Antiviral screen identifies EV71 inhibitors and reveals camptothecin-target, DNA topoisomerase 1 as a novel EV71 host factor
Enterovirus 71 (EV71) is one of the causative agents of hand, foot and mouth disease (HFMD) associated with severe neurological disease. EV71's pathogenesis remains poorly understood and the lack of approved antiviral has led to its emergence as a clinically important neurotropic virus. The goa...
Gespeichert in:
Veröffentlicht in: | Antiviral research 2017-07, Vol.143, p.122-133 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 133 |
---|---|
container_issue | |
container_start_page | 122 |
container_title | Antiviral research |
container_volume | 143 |
creator | Wu, Kan Xing Chu, Justin Jang-Hann |
description | Enterovirus 71 (EV71) is one of the causative agents of hand, foot and mouth disease (HFMD) associated with severe neurological disease. EV71's pathogenesis remains poorly understood and the lack of approved antiviral has led to its emergence as a clinically important neurotropic virus. The goals of this study were to: (i) identify novel anti-EV71 compounds that may serve as lead molecules for therapeutics; and (ii) investigate their targets in downstream studies. We screened a 502-compound library of highly purified natural products for anti-EV71 activities in a cell-based immunofluorescence assay that were then confirmed in viral plaque reduction assays. Along with known antivirals, novel inhibitors of EV71 were also identified. We selected camptothecin for downstream studies and found that it is a limited spectrum enterovirus inhibitor that inhibits coxsackievirus A16 but not ECHOvirus 7. Camptothecin, a DNA topoisomerase 1 (TOP1) inhibitor, inhibits both viral RNA replication and translation based on luciferase replicon studies. Depletion of TOP1 using siRNA was then able to rescue EV71 infection from camptothecin inhibition. Interestingly, EV71 viral RNA replication and translation were also in TOP1 depleted cells. We found that nuclear TOP1 was relocalized to cytoplasmic replication vesicles during EV71 infection and localized with viral 3CD using confocal microscopy and proximity-ligation assays. Our findings reveal camptothecin to be a limited spectrum antiviral against enteroviruses that functions in a TOP1-dependent but cytotoxicity-independent manner. TOP1 is in turn needed for maximal EV71 viral RNA replication and viral protein synthesis.
[Display omitted]
•We screened a 502-compound library of highly purified natural products for anti-enterovirus 71 activities.•Camptothecin was found to be a limited spectrum antiviral that also inhibits coxsackievirus A16 but not ECHOvirus 7.•DNA topoisomerase 1 (TOP1)-depletion was able to rescue EV71 infection, revealing a mechanism that acts through TOP1.•Typically nuclear TOP1 was relocalized to replication vesicles during EV71 infection and localizes with viral 3CD.•Our findings reveal TOP1 as an EV71 host factor and this interaction allows for antiviral targeting by camptothecin. |
doi_str_mv | 10.1016/j.antiviral.2017.04.008 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1891130678</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166354217301584</els_id><sourcerecordid>1891130678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-7a3f0e0906d1744ccbd7269dc42439d592771ae7cefac4f8a8954af29e1918c33</originalsourceid><addsrcrecordid>eNqFkE1PGzEQhq2qqATav0B97IFdbK-zto9RypeE4AJcLceeJY5216ntrITUH49RCFdOI43e9xnNg9BvSmpKaHuxqc2Y_eSj6WtGqKgJrwmR39CMSsEqRVT7Hc1Ksq2aOWfH6CSlDSGkFUr-QMdMciYkEzP0f3Hg4GQjwIi9g7LqPCR8-Swo9uPar3wOMWEzOhxhAtMnbM2wzSGvwfqxyia-QD7Hf-8XOIdt8CkMEE0CTLEpPTyGCfo9bx1Sxp2xhfgTHXWFBb8-5il6urp8XN5Udw_Xt8vFXWUbQXMlTNMRIIq0jgrOrV05wVrlLGe8UW6umBDUgLBQsLyTRqo5Nx1TQBWVtmlO0Z89dxvDvx2krAefLPS9GSHskqZSUdoUObJExT5qY0gpQqe30Q8mvmpK9Lt6vdGf6vW7ek24LupL8-zjyG41gPvsHVyXwGIfgPLq5CHqZD2MFpyPYLN2wX955A1uDJo_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1891130678</pqid></control><display><type>article</type><title>Antiviral screen identifies EV71 inhibitors and reveals camptothecin-target, DNA topoisomerase 1 as a novel EV71 host factor</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wu, Kan Xing ; Chu, Justin Jang-Hann</creator><creatorcontrib>Wu, Kan Xing ; Chu, Justin Jang-Hann</creatorcontrib><description>Enterovirus 71 (EV71) is one of the causative agents of hand, foot and mouth disease (HFMD) associated with severe neurological disease. EV71's pathogenesis remains poorly understood and the lack of approved antiviral has led to its emergence as a clinically important neurotropic virus. The goals of this study were to: (i) identify novel anti-EV71 compounds that may serve as lead molecules for therapeutics; and (ii) investigate their targets in downstream studies. We screened a 502-compound library of highly purified natural products for anti-EV71 activities in a cell-based immunofluorescence assay that were then confirmed in viral plaque reduction assays. Along with known antivirals, novel inhibitors of EV71 were also identified. We selected camptothecin for downstream studies and found that it is a limited spectrum enterovirus inhibitor that inhibits coxsackievirus A16 but not ECHOvirus 7. Camptothecin, a DNA topoisomerase 1 (TOP1) inhibitor, inhibits both viral RNA replication and translation based on luciferase replicon studies. Depletion of TOP1 using siRNA was then able to rescue EV71 infection from camptothecin inhibition. Interestingly, EV71 viral RNA replication and translation were also in TOP1 depleted cells. We found that nuclear TOP1 was relocalized to cytoplasmic replication vesicles during EV71 infection and localized with viral 3CD using confocal microscopy and proximity-ligation assays. Our findings reveal camptothecin to be a limited spectrum antiviral against enteroviruses that functions in a TOP1-dependent but cytotoxicity-independent manner. TOP1 is in turn needed for maximal EV71 viral RNA replication and viral protein synthesis.
[Display omitted]
•We screened a 502-compound library of highly purified natural products for anti-enterovirus 71 activities.•Camptothecin was found to be a limited spectrum antiviral that also inhibits coxsackievirus A16 but not ECHOvirus 7.•DNA topoisomerase 1 (TOP1)-depletion was able to rescue EV71 infection, revealing a mechanism that acts through TOP1.•Typically nuclear TOP1 was relocalized to replication vesicles during EV71 infection and localizes with viral 3CD.•Our findings reveal TOP1 as an EV71 host factor and this interaction allows for antiviral targeting by camptothecin.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2017.04.008</identifier><identifier>PMID: 28427827</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antibodies, Monoclonal ; Antibodies, Viral ; Antiviral Agents - isolation & purification ; Antiviral Agents - pharmacology ; Biological Products - pharmacology ; Camptothecin - antagonists & inhibitors ; Cell Line ; Cell Survival ; DNA Topoisomerases, Type I - drug effects ; Drug Evaluation, Preclinical ; Enterovirus - drug effects ; Enterovirus A, Human - drug effects ; Enterovirus A, Human - pathogenicity ; Enterovirus Infections - drug therapy ; Gene Knockdown Techniques ; Goats ; Luciferases ; Mice ; Microscopy, Confocal ; Rabbits ; Replicon - drug effects ; RNA, Small Interfering - genetics ; Viral Proteins - drug effects ; Viral Proteins - metabolism ; Virus Replication - drug effects</subject><ispartof>Antiviral research, 2017-07, Vol.143, p.122-133</ispartof><rights>2017 Elsevier B.V.</rights><rights>Copyright © 2017 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-7a3f0e0906d1744ccbd7269dc42439d592771ae7cefac4f8a8954af29e1918c33</citedby><cites>FETCH-LOGICAL-c371t-7a3f0e0906d1744ccbd7269dc42439d592771ae7cefac4f8a8954af29e1918c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0166354217301584$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28427827$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Kan Xing</creatorcontrib><creatorcontrib>Chu, Justin Jang-Hann</creatorcontrib><title>Antiviral screen identifies EV71 inhibitors and reveals camptothecin-target, DNA topoisomerase 1 as a novel EV71 host factor</title><title>Antiviral research</title><addtitle>Antiviral Res</addtitle><description>Enterovirus 71 (EV71) is one of the causative agents of hand, foot and mouth disease (HFMD) associated with severe neurological disease. EV71's pathogenesis remains poorly understood and the lack of approved antiviral has led to its emergence as a clinically important neurotropic virus. The goals of this study were to: (i) identify novel anti-EV71 compounds that may serve as lead molecules for therapeutics; and (ii) investigate their targets in downstream studies. We screened a 502-compound library of highly purified natural products for anti-EV71 activities in a cell-based immunofluorescence assay that were then confirmed in viral plaque reduction assays. Along with known antivirals, novel inhibitors of EV71 were also identified. We selected camptothecin for downstream studies and found that it is a limited spectrum enterovirus inhibitor that inhibits coxsackievirus A16 but not ECHOvirus 7. Camptothecin, a DNA topoisomerase 1 (TOP1) inhibitor, inhibits both viral RNA replication and translation based on luciferase replicon studies. Depletion of TOP1 using siRNA was then able to rescue EV71 infection from camptothecin inhibition. Interestingly, EV71 viral RNA replication and translation were also in TOP1 depleted cells. We found that nuclear TOP1 was relocalized to cytoplasmic replication vesicles during EV71 infection and localized with viral 3CD using confocal microscopy and proximity-ligation assays. Our findings reveal camptothecin to be a limited spectrum antiviral against enteroviruses that functions in a TOP1-dependent but cytotoxicity-independent manner. TOP1 is in turn needed for maximal EV71 viral RNA replication and viral protein synthesis.
[Display omitted]
•We screened a 502-compound library of highly purified natural products for anti-enterovirus 71 activities.•Camptothecin was found to be a limited spectrum antiviral that also inhibits coxsackievirus A16 but not ECHOvirus 7.•DNA topoisomerase 1 (TOP1)-depletion was able to rescue EV71 infection, revealing a mechanism that acts through TOP1.•Typically nuclear TOP1 was relocalized to replication vesicles during EV71 infection and localizes with viral 3CD.•Our findings reveal TOP1 as an EV71 host factor and this interaction allows for antiviral targeting by camptothecin.</description><subject>Animals</subject><subject>Antibodies, Monoclonal</subject><subject>Antibodies, Viral</subject><subject>Antiviral Agents - isolation & purification</subject><subject>Antiviral Agents - pharmacology</subject><subject>Biological Products - pharmacology</subject><subject>Camptothecin - antagonists & inhibitors</subject><subject>Cell Line</subject><subject>Cell Survival</subject><subject>DNA Topoisomerases, Type I - drug effects</subject><subject>Drug Evaluation, Preclinical</subject><subject>Enterovirus - drug effects</subject><subject>Enterovirus A, Human - drug effects</subject><subject>Enterovirus A, Human - pathogenicity</subject><subject>Enterovirus Infections - drug therapy</subject><subject>Gene Knockdown Techniques</subject><subject>Goats</subject><subject>Luciferases</subject><subject>Mice</subject><subject>Microscopy, Confocal</subject><subject>Rabbits</subject><subject>Replicon - drug effects</subject><subject>RNA, Small Interfering - genetics</subject><subject>Viral Proteins - drug effects</subject><subject>Viral Proteins - metabolism</subject><subject>Virus Replication - drug effects</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1PGzEQhq2qqATav0B97IFdbK-zto9RypeE4AJcLceeJY5216ntrITUH49RCFdOI43e9xnNg9BvSmpKaHuxqc2Y_eSj6WtGqKgJrwmR39CMSsEqRVT7Hc1Ksq2aOWfH6CSlDSGkFUr-QMdMciYkEzP0f3Hg4GQjwIi9g7LqPCR8-Swo9uPar3wOMWEzOhxhAtMnbM2wzSGvwfqxyia-QD7Hf-8XOIdt8CkMEE0CTLEpPTyGCfo9bx1Sxp2xhfgTHXWFBb8-5il6urp8XN5Udw_Xt8vFXWUbQXMlTNMRIIq0jgrOrV05wVrlLGe8UW6umBDUgLBQsLyTRqo5Nx1TQBWVtmlO0Z89dxvDvx2krAefLPS9GSHskqZSUdoUObJExT5qY0gpQqe30Q8mvmpK9Lt6vdGf6vW7ek24LupL8-zjyG41gPvsHVyXwGIfgPLq5CHqZD2MFpyPYLN2wX955A1uDJo_</recordid><startdate>201707</startdate><enddate>201707</enddate><creator>Wu, Kan Xing</creator><creator>Chu, Justin Jang-Hann</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201707</creationdate><title>Antiviral screen identifies EV71 inhibitors and reveals camptothecin-target, DNA topoisomerase 1 as a novel EV71 host factor</title><author>Wu, Kan Xing ; Chu, Justin Jang-Hann</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-7a3f0e0906d1744ccbd7269dc42439d592771ae7cefac4f8a8954af29e1918c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal</topic><topic>Antibodies, Viral</topic><topic>Antiviral Agents - isolation & purification</topic><topic>Antiviral Agents - pharmacology</topic><topic>Biological Products - pharmacology</topic><topic>Camptothecin - antagonists & inhibitors</topic><topic>Cell Line</topic><topic>Cell Survival</topic><topic>DNA Topoisomerases, Type I - drug effects</topic><topic>Drug Evaluation, Preclinical</topic><topic>Enterovirus - drug effects</topic><topic>Enterovirus A, Human - drug effects</topic><topic>Enterovirus A, Human - pathogenicity</topic><topic>Enterovirus Infections - drug therapy</topic><topic>Gene Knockdown Techniques</topic><topic>Goats</topic><topic>Luciferases</topic><topic>Mice</topic><topic>Microscopy, Confocal</topic><topic>Rabbits</topic><topic>Replicon - drug effects</topic><topic>RNA, Small Interfering - genetics</topic><topic>Viral Proteins - drug effects</topic><topic>Viral Proteins - metabolism</topic><topic>Virus Replication - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Kan Xing</creatorcontrib><creatorcontrib>Chu, Justin Jang-Hann</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Kan Xing</au><au>Chu, Justin Jang-Hann</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiviral screen identifies EV71 inhibitors and reveals camptothecin-target, DNA topoisomerase 1 as a novel EV71 host factor</atitle><jtitle>Antiviral research</jtitle><addtitle>Antiviral Res</addtitle><date>2017-07</date><risdate>2017</risdate><volume>143</volume><spage>122</spage><epage>133</epage><pages>122-133</pages><issn>0166-3542</issn><eissn>1872-9096</eissn><abstract>Enterovirus 71 (EV71) is one of the causative agents of hand, foot and mouth disease (HFMD) associated with severe neurological disease. EV71's pathogenesis remains poorly understood and the lack of approved antiviral has led to its emergence as a clinically important neurotropic virus. The goals of this study were to: (i) identify novel anti-EV71 compounds that may serve as lead molecules for therapeutics; and (ii) investigate their targets in downstream studies. We screened a 502-compound library of highly purified natural products for anti-EV71 activities in a cell-based immunofluorescence assay that were then confirmed in viral plaque reduction assays. Along with known antivirals, novel inhibitors of EV71 were also identified. We selected camptothecin for downstream studies and found that it is a limited spectrum enterovirus inhibitor that inhibits coxsackievirus A16 but not ECHOvirus 7. Camptothecin, a DNA topoisomerase 1 (TOP1) inhibitor, inhibits both viral RNA replication and translation based on luciferase replicon studies. Depletion of TOP1 using siRNA was then able to rescue EV71 infection from camptothecin inhibition. Interestingly, EV71 viral RNA replication and translation were also in TOP1 depleted cells. We found that nuclear TOP1 was relocalized to cytoplasmic replication vesicles during EV71 infection and localized with viral 3CD using confocal microscopy and proximity-ligation assays. Our findings reveal camptothecin to be a limited spectrum antiviral against enteroviruses that functions in a TOP1-dependent but cytotoxicity-independent manner. TOP1 is in turn needed for maximal EV71 viral RNA replication and viral protein synthesis.
[Display omitted]
•We screened a 502-compound library of highly purified natural products for anti-enterovirus 71 activities.•Camptothecin was found to be a limited spectrum antiviral that also inhibits coxsackievirus A16 but not ECHOvirus 7.•DNA topoisomerase 1 (TOP1)-depletion was able to rescue EV71 infection, revealing a mechanism that acts through TOP1.•Typically nuclear TOP1 was relocalized to replication vesicles during EV71 infection and localizes with viral 3CD.•Our findings reveal TOP1 as an EV71 host factor and this interaction allows for antiviral targeting by camptothecin.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28427827</pmid><doi>10.1016/j.antiviral.2017.04.008</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0166-3542 |
ispartof | Antiviral research, 2017-07, Vol.143, p.122-133 |
issn | 0166-3542 1872-9096 |
language | eng |
recordid | cdi_proquest_miscellaneous_1891130678 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Animals Antibodies, Monoclonal Antibodies, Viral Antiviral Agents - isolation & purification Antiviral Agents - pharmacology Biological Products - pharmacology Camptothecin - antagonists & inhibitors Cell Line Cell Survival DNA Topoisomerases, Type I - drug effects Drug Evaluation, Preclinical Enterovirus - drug effects Enterovirus A, Human - drug effects Enterovirus A, Human - pathogenicity Enterovirus Infections - drug therapy Gene Knockdown Techniques Goats Luciferases Mice Microscopy, Confocal Rabbits Replicon - drug effects RNA, Small Interfering - genetics Viral Proteins - drug effects Viral Proteins - metabolism Virus Replication - drug effects |
title | Antiviral screen identifies EV71 inhibitors and reveals camptothecin-target, DNA topoisomerase 1 as a novel EV71 host factor |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T03%3A11%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiviral%20screen%20identifies%20EV71%20inhibitors%20and%20reveals%20camptothecin-target,%20DNA%20topoisomerase%201%20as%20a%20novel%20EV71%20host%20factor&rft.jtitle=Antiviral%20research&rft.au=Wu,%20Kan%20Xing&rft.date=2017-07&rft.volume=143&rft.spage=122&rft.epage=133&rft.pages=122-133&rft.issn=0166-3542&rft.eissn=1872-9096&rft_id=info:doi/10.1016/j.antiviral.2017.04.008&rft_dat=%3Cproquest_cross%3E1891130678%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1891130678&rft_id=info:pmid/28427827&rft_els_id=S0166354217301584&rfr_iscdi=true |